MedTrace Logo

Selective Dose Escalation for Esophageal Cancer

NCT00139633 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2005-08-31

No results posted yet for this study

Summary

This prospective study was designed to assess the outcomes (survival and failure patterns) of therapy for localized esophageal cancer with conventional dose radiation (RT; 50.4 Gy) with concurrent continuous infusion 5-fluorouracil (5-FU) and weekly carboplatin/paclitaxel. Patients with less than complete response (CR) or partial response (PR) received dose escalation of radiation to 59.4 Gy with the same chemotherapy.

Conditions

  • Esophageal Cancer

Interventions

DRUG

carboplatin, 5FU, Taxol and radiation

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • MedImmune LLC

    collaborator INDUSTRY

  • The Oregon Clinic

    lead OTHER

Principal Investigators

  • Steven K Seung, MDPhD · The Oregon Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00139633 on ClinicalTrials.gov